结论：苯扎贝特表现出很重要的临床抗糖尿病属性。
CONCLUSIONS - Bezafibrate appears to have clinically important antidiabetic properties.
采用事后分析以口服抗糖尿病药或胰岛素做基准检测苯扎贝特的效果。
A post hoc analysis was used to examine the effect of bezafibrate on progression to use of oral antidiabetic medications or insulin in individuals with diabetes at baseline.
应该考虑随机对照临床试验来评价苯扎贝特治疗糖尿病或者预防高危人群患糖尿病的功效。
Randomized controlled trials should be considered to assess the utility of bezafibrate in treating patients with diabetes or in preventing diabetes in high-risk patients.
应该考虑随机对照临床试验来评价苯扎贝特治疗糖尿病或者预防高危人群患糖尿病的功效。
Randomized controlled trials should be considered to assess the utility of bezafibrate in treating patients with diabetes or in preventing diabetes in high-risk patients.
应用推荐